Wealth Enhancement Advisory Services LLC Has $303,000 Holdings in Envista Holdings Co. (NYSE:NVST)

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Envista Holdings Co. (NYSE:NVST) by 11.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,314 shares of the company’s stock after purchasing an additional 1,538 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Envista were worth $303,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of NVST. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Envista in the 3rd quarter worth about $31,000. GAMMA Investing LLC raised its position in shares of Envista by 69.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after acquiring an additional 726 shares during the period. Blue Trust Inc. raised its position in shares of Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Envista by 50.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares during the period. Finally, Versant Capital Management Inc raised its position in shares of Envista by 1,420.3% in the 2nd quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock valued at $52,000 after acquiring an additional 2,940 shares during the period.

Envista Price Performance

NYSE:NVST opened at $20.39 on Monday. Envista Holdings Co. has a 1-year low of $15.15 and a 1-year high of $25.64. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The firm has a fifty day simple moving average of $18.92 and a 200 day simple moving average of $18.11.

Envista (NYSE:NVST) last released its earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The business had revenue of $601.00 million during the quarter, compared to analysts’ expectations of $590.34 million. During the same period last year, the business earned $0.43 earnings per share. The firm’s revenue was down 4.8% on a year-over-year basis. On average, sell-side analysts expect that Envista Holdings Co. will post 0.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on NVST. Stifel Nicolaus raised their target price on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Leerink Partnrs upgraded shares of Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Piper Sandler raised their target price on shares of Envista from $16.00 to $17.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Robert W. Baird raised their target price on shares of Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, October 31st. Finally, JPMorgan Chase & Co. downgraded shares of Envista from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $23.00 to $16.00 in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $20.71.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.